EP2201034A4 - PROTECTION OF NERVES WITH NAP-SIMILAR AND SAL-SIMILAR PEPTIDE MIMETICS - Google Patents

PROTECTION OF NERVES WITH NAP-SIMILAR AND SAL-SIMILAR PEPTIDE MIMETICS

Info

Publication number: EP2201034A4
Authority: EP; European Patent Office
Prior art keywords: neuroprotection; nap; ensured; peptide mimetics; sal type
Prior art date: 2007-08-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP08783406A

Other languages

German (de)

English (en)

French (fr)

Other versions

EP2201034A1 (en

Inventor

Illana Gozes

Alistair Stewart

Maya Maor

Sharon Furman-Assaf

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ramot at Tel Aviv University Ltd

Original Assignee

Allon Therapeutics Inc

Ramot at Tel Aviv University Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-24

Filing date

2008-08-22

Publication date

2011-05-18

2008-08-22 Application filed by Allon Therapeutics Inc, Ramot at Tel Aviv University Ltd filed Critical Allon Therapeutics Inc

2010-06-30 Publication of EP2201034A1 publication Critical patent/EP2201034A1/en

2011-05-18 Publication of EP2201034A4 publication Critical patent/EP2201034A4/en

Status Withdrawn legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Addiction (AREA)
Zoology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

EP08783406A 2007-08-24 2008-08-22 PROTECTION OF NERVES WITH NAP-SIMILAR AND SAL-SIMILAR PEPTIDE MIMETICS Withdrawn EP2201034A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US95779007P	2007-08-24	2007-08-24
PCT/CA2008/001497 WO2009026687A1 (en)	2007-08-24	2008-08-22	Neuroprotection using nap-like and sal-like peptide mimetics

Publications (2)

Publication Number	Publication Date
EP2201034A1 EP2201034A1 (en)	2010-06-30
EP2201034A4 true EP2201034A4 (en)	2011-05-18

Family

ID=40386607

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP08783406A Withdrawn EP2201034A4 (en)	2007-08-24	2008-08-22	PROTECTION OF NERVES WITH NAP-SIMILAR AND SAL-SIMILAR PEPTIDE MIMETICS

Country Status (12)

Country	Link
US (2)	US8324166B2 (pt)
EP (1)	EP2201034A4 (pt)
JP (1)	JP2010536801A (pt)
KR (1)	KR20100063719A (pt)
CN (1)	CN101848934A (pt)
AU (1)	AU2008291652A1 (pt)
BR (1)	BRPI0815752A2 (pt)
CA (1)	CA2695559A1 (pt)
MX (1)	MX2010001936A (pt)
NZ (1)	NZ583260A (pt)
RU (1)	RU2010111114A (pt)
WO (1)	WO2009026687A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6613740B1 (en) *	1997-02-07	2003-09-02	Ramot University Authority For Applied Research And Industrial Development Ltd.	Activity dependent neurotrophic factor III (ADNF III)
US7384908B1 (en) *	1999-08-18	2008-06-10	National Institute Of Health	Orally active peptides that prevent cell damage and death
WO2003022226A2 (en) *	2001-09-12	2003-03-20	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Neurotrophic components of the adnf i complex
WO2004080957A2 (en) *	2003-03-12	2004-09-23	Ramot At Tel Aviv University Ltd.	Use of adnf polypeptides for treating anxiety and depression
WO2006099739A1 (en) *	2005-03-23	2006-09-28	Ramot At Tel-Aviv University Ltd.	Use of adnf polypeptides for treating peripheral neurotoxicity
US8067369B2 (en) *	2006-02-24	2011-11-29	Ramot At Tel-Aviv University	Protection of the retina against laser injury by NAP and related peptides
WO2011021186A1 (en) *	2009-08-17	2011-02-24	Ramot At Tel-Aviv University, Ltd.	Nap alpha-aminoisobutyric acid analog with neuroprotective activity
US9518994B2 (en)	2010-01-06	2016-12-13	Ramot At Tel Aviv University	Method for diagnosing and monitoring schizophrenia and tauopathies
WO2012015910A2 (en) *	2010-07-28	2012-02-02	Allon Therapeutics Inc.	Use of adnf polypeptides for treating neurodegenerative diseases
US10118943B2 (en) *	2012-05-16	2018-11-06	Ramot At Tel-Aviv University Ltd.	Compounds and methods for inhibiting cell death
CN105017406B (zh) *	2014-04-21	2020-10-09	上海市第一人民医院	一类新的具有神经保护功能的多肽
US10912819B2 (en) *	2016-01-28	2021-02-09	Ramot At Tel-Aviv University, Ltd.	Neuroprotective peptides derived from activity-dependent neuroprotective protein for treatment of neurological diseases
US10100082B2 (en) *	2016-03-07	2018-10-16	Council Of Scientific And Industrial Research	Hexapeptide for neuroprotection against a β toxicity
JP6727962B2 (ja) *	2016-07-08	2020-07-22	学校法人慶應義塾	癌の予防又は治療剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000027875A2 (en) *	1998-11-06	2000-05-18	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Activity dependent neurotrophic factor iii (adnf iii)
US6174862B1 (en) *	1991-04-22	2001-01-16	Ramot University Authority For Applied Research And Industrial Development, Ltd.	Neurotrophic peptides of activity dependent neurotrophic factor
WO2001012654A2 (en) *	1999-08-18	2001-02-22	Ramot University Authority For Applied Research & Industrial Development Ltd.	Orally active peptides that prevent cell damage and death
WO2001075067A2 (en) *	2000-03-31	2001-10-11	Hyseq, Inc.	Novel nucleic acids and polypeptides
US20070142269A1 (en) *	2005-12-20	2007-06-21	Industrial Technology Research Institute	Oligopeptide, derivatives thereof, and pharmaceutical composition comprising the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6933277B2 (en)	1999-03-12	2005-08-23	The United States Of America As Represented By The Department Of Health And Human Services	Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
US6649411B2 (en)	1999-07-30	2003-11-18	The United States Of America As Represented By The Department Of Health And Human Services	Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides
US7384908B1 (en)	1999-08-18	2008-06-10	National Institute Of Health	Orally active peptides that prevent cell damage and death
AUPQ776100A0 (en) *	2000-05-26	2000-06-15	Australian National University, The	Synthetic molecules and uses therefor
CN1444600A (zh)	2000-05-31	2003-09-24	美国政府健康及人类服务部	用于增强学习和记忆的活性依赖性神经营养因子衍生的多肽的使用:出生前后的给药
WO2003022226A2 (en)	2001-09-12	2003-03-20	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Neurotrophic components of the adnf i complex
WO2004080957A2 (en)	2003-03-12	2004-09-23	Ramot At Tel Aviv University Ltd.	Use of adnf polypeptides for treating anxiety and depression
WO2006099739A1 (en)	2005-03-23	2006-09-28	Ramot At Tel-Aviv University Ltd.	Use of adnf polypeptides for treating peripheral neurotoxicity
US8067369B2 (en)	2006-02-24	2011-11-29	Ramot At Tel-Aviv University	Protection of the retina against laser injury by NAP and related peptides

2008
- 2008-08-22 AU AU2008291652A patent/AU2008291652A1/en not_active Abandoned
- 2008-08-22 CA CA2695559A patent/CA2695559A1/en not_active Abandoned
- 2008-08-22 EP EP08783406A patent/EP2201034A4/en not_active Withdrawn
- 2008-08-22 MX MX2010001936A patent/MX2010001936A/es active IP Right Grant
- 2008-08-22 JP JP2010521273A patent/JP2010536801A/ja active Pending
- 2008-08-22 RU RU2010111114/10A patent/RU2010111114A/ru not_active Application Discontinuation
- 2008-08-22 KR KR1020107005812A patent/KR20100063719A/ko not_active Withdrawn
- 2008-08-22 CN CN200880104001A patent/CN101848934A/zh active Pending
- 2008-08-22 BR BRPI0815752-9A2A patent/BRPI0815752A2/pt not_active IP Right Cessation
- 2008-08-22 NZ NZ583260A patent/NZ583260A/en not_active IP Right Cessation
- 2008-08-22 WO PCT/CA2008/001497 patent/WO2009026687A1/en not_active Ceased
2010
- 2010-02-18 US US12/708,384 patent/US8324166B2/en not_active Expired - Fee Related
2012
- 2012-10-30 US US13/664,168 patent/US20130123186A1/en not_active Abandoned

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6174862B1 (en) *	1991-04-22	2001-01-16	Ramot University Authority For Applied Research And Industrial Development, Ltd.	Neurotrophic peptides of activity dependent neurotrophic factor
WO2000027875A2 (en) *	1998-11-06	2000-05-18	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Activity dependent neurotrophic factor iii (adnf iii)
WO2001012654A2 (en) *	1999-08-18	2001-02-22	Ramot University Authority For Applied Research & Industrial Development Ltd.	Orally active peptides that prevent cell damage and death
WO2001075067A2 (en) *	2000-03-31	2001-10-11	Hyseq, Inc.	Novel nucleic acids and polypeptides
US20070142269A1 (en) *	2005-12-20	2007-06-21	Industrial Technology Research Institute	Oligopeptide, derivatives thereof, and pharmaceutical composition comprising the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009026687A1 *

Also Published As

Publication number	Publication date
US20100216723A1 (en)	2010-08-26
US8324166B2 (en)	2012-12-04
CN101848934A (zh)	2010-09-29
US20130123186A1 (en)	2013-05-16
WO2009026687A1 (en)	2009-03-05
MX2010001936A (es)	2010-08-09
AU2008291652A1 (en)	2009-03-05
EP2201034A1 (en)	2010-06-30
KR20100063719A (ko)	2010-06-11
NZ583260A (en)	2012-07-27
RU2010111114A (ru)	2011-09-27
JP2010536801A (ja)	2010-12-02
CA2695559A1 (en)	2009-03-05
BRPI0815752A2 (pt)	2015-02-18

Legal Events

Date	Code	Title	Description
2010-05-28	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2010-06-30	17P	Request for examination filed	Effective date: 20100318
2010-06-30	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2010-06-30	AX	Request for extension of the european patent	Extension state: AL BA MK RS
2010-12-01	DAX	Request for extension of the european patent (deleted)
2011-05-18	A4	Supplementary search report drawn up and despatched	Effective date: 20110418
2012-07-06	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1144950 Country of ref document: HK
2014-09-17	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: RAMOT AT TEL-AVIV UNIVERSITY LTD.
2014-11-26	17Q	First examination report despatched	Effective date: 20141023
2015-07-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2015-08-19	18D	Application deemed to be withdrawn	Effective date: 20150303
2018-03-23	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1144950 Country of ref document: HK

Publication	Publication Date	Title
EP2201034A4 (en)	2011-05-18	PROTECTION OF NERVES WITH NAP-SIMILAR AND SAL-SIMILAR PEPTIDE MIMETICS
BRPI0911743A2 (pt)	2015-07-07	"peptídeo"
EP2004020A4 (en)	2013-10-02	SEAT ARRANGEMENT
EP1939032A4 (en)	2009-07-22	SEAT
EP2217064A4 (en)	2012-10-03	NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES
EP2307038A4 (en)	2013-03-27	ELASTIC PEPTIDES COMPREHENSIVE THERAPEUTIC AGENTS
EP1942028A4 (en)	2009-07-22	SEAT
EP2167528A4 (en)	2011-01-19	MODIFIED TOXINS
ATE534660T1 (de)	2011-12-15	Peptidsequenzen und zusammensetzungen
DE602009000268D1 (de)	2010-11-25	Schaltsystem und Motorrad
ATE526567T1 (de)	2011-10-15	Zusammensteller und zusammenstellungsverfahren
EP1944192A4 (en)	2009-07-22	SEAT
DK2051606T3 (da)	2013-01-28	Lænestol
DK2035451T3 (da)	2010-06-07	Insulinoptrop peptidsyntese
EP2008963A4 (en)	2012-02-01	SEAT
DK2133416T3 (da)	2014-11-10	Rekombinant mikroorganisme
ZA200902300B (en)	2010-10-27	Use of modified cyclosporins
DE112007002757A5 (de)	2009-08-20	Stuhl
DK2021364T3 (da)	2014-07-07	Forbedrede antimikrobielle peptider
DK1985695T3 (da)	2013-03-11	Rekombinant mikroorganisme
DK2152881T3 (da)	2014-07-14	RumC-peptider med antimikrobiel aktivitet
BRPI0815379A2 (pt)	2017-05-23	peptídeos modificados tendo efeitos intesificadores de toxina
FI20075483A0 (fi)	2007-06-25	Uusi peptidi
DK2081952T3 (da)	2014-04-28	Peptider
EP2195338A4 (en)	2010-11-03	N-TERMINAL MODIFIED INTERFERON ALPHA